Publications
Detailed Information
Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Eun Hee | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Kim, Sung-Yong | - |
dc.contributor.author | Park, Young | - |
dc.contributor.author | Yuh, Young Jin | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Lee, Won-Sik | - |
dc.contributor.author | Park, Sung-Kyu | - |
dc.contributor.author | Bang, Soo Mee | - |
dc.date.accessioned | 2022-10-17T04:16:41Z | - |
dc.date.available | 2022-10-17T04:16:41Z | - |
dc.date.created | 2022-10-14 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.citation | Clinical Lymphoma Myeloma & Leukemia, Vol.22 No.10, pp.e931-e937 | - |
dc.identifier.issn | 2152-2650 | - |
dc.identifier.uri | https://hdl.handle.net/10371/186143 | - |
dc.description.abstract | © 2022Introduction/Background: Ruxolitinib is an established treatment for myelofibrosis (MF) that has demonstrated clinical benefit by reducing spleen size and debilitating MF-related symptoms. However, despite the efficacy of ruxolitinib, anemia remains a major adverse event that causes dose modification or discontinuation in real-world practice. Additionally, dependence on red blood cell (RBC) transfusion (TF) is common during treatment; therefore, we explored the outcome of ruxolitinib therapy with a primary focus on RBC TF. Patients/Methods: We retrospectively reviewed the medical records of 123 MF patients treated with ruxolitinib between January 2012 and April 2020 at eight academic centers in Korea. Results: At ruxolitinib initiation, 38 patients (30.9%) underwent ≥ 2 units of RBC TF over 8 weeks. The most common reason for permanent discontinuation was intolerant anemia (10/63, 15.9%). The most common reasons for temporary interruption were nonhematologic toxicity (26/55, 21.1%), anemia (23/55, 18.7%) and thrombocytopenia (13/55, 10.6%). Among the 123 patients in the study, 57 (46.3%), 42 (34.1%), and 40 patients (32.5%) who were receiving or stopped ruxolitinib therapy had a status of RBC TF dependence, long-term RBC TF dependence, or severe RBC TF dependence, respectively. The presence of ≥ 2 units of RBC transfusion over 8 weeks at ruxolitinib initiation was an independent risk factor for persistent RBC TF dependence. Conclusion: The requirement for RBC TF is commonly encountered during treatment of MF with ruxolitinib, particularly among those with pre-existing ≥ 2 units of RBC TF over 8 weeks. For those patients, overcoming the barrier of maintenance TF is demanding. | - |
dc.language | 영어 | - |
dc.publisher | CIG MEDIA GROUP, LP | - |
dc.title | Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.clml.2022.06.008 | - |
dc.citation.journaltitle | Clinical Lymphoma Myeloma & Leukemia | - |
dc.identifier.scopusid | 2-s2.0-85134617475 | - |
dc.citation.endpage | e937 | - |
dc.citation.number | 10 | - |
dc.citation.startpage | e931 | - |
dc.citation.volume | 22 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Hong, Junshik | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.